HTB

FDA approves dispersible dolutegravir/abacavir/3TC for children

Simon Collins, HIV i-Base

On 30 March 2022, the US FDA approved a single tablet regimen of dolutegravir/abacavir/3TC in a dispersible formulation for children weighing 10 kgs to 25 kgs.

This will provide a simpler and easier to take option for children living with HIV.

Reference

ViiV Healthcare. ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV. (30 March 2022).
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv

Links to other websites are current at date of posting but not maintained.